Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members
Helix BioPharma Corp. announced the appointment of Artur Gabor as the new Chief Executive Officer and added three new members to its Board of Directors aimed at enhancing corporate governance and growth capabilities. The new board members include Jerzy Leszczyński, Christopher Maciejewski, and Jacek Antas, each bringing significant experience in their respective fields. This leadership change is expected to bolster the company's strategic direction in immuno-oncology therapies based on the proprietary DOS47 platform.
- Appointment of Artur Gabor as CEO could bring fresh perspective and direction.
- Addition of experienced board members may strengthen corporate governance.
- None.
RICHMOND HILL, ON / ACCESSWIRE / April 18, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platformDOS47, is pleased to announce that Artur Gabor has been appointed as the Company's Chief Executive Officer with immediate effect.
The Company is also pleased to announce the addition of three new members to its Board of Directors (the "Board"). Jerzy Leszczyński, Christopher Maciejewski and Jacek Antas have been appointed to the Board effective immediately. These appointments are designed to improve the Company's independence, diversification and corporate governance with an aim of strengthening the Company's future growth capabilities.
Jerzy Leszczyński is a shareholder of the Company, has spent more than 35 years developing businesses and has served in the capacity of board member of various real estate development companies. Mr. Leszczyński obtained his Masters of Science in Chemistry from the Warsaw Institute of Technology.
Christopher Maciejewski is a consultant to an international flight medicine transport service. Prior to this role, Mr. Maciejewsi served as the Chief Medical Officer of MedEvac Canada, a leading non-emergency patient transfer company. He has spent more than thirty years building and leading businesses in medical field, specifically within air ambulance transport. Mr. Maciejewski has an extensive educational background and attended Silesian University in Wroclaw, Poland where he studied Applied Medical Manual Sciences. Mr. Maciejewski is based in Toronto, Ontario, Canada.
Jacek Antas has spent more than 25 years in the financial services industry holding various positions in sales and consulting. Mr. Antas obtained a master's degree from the Warsaw School of Economics and has served as a board member of various companies throughout his career.
"It's a pleasure to welcome these three distinguished members to join the Board of Helix. I look forward to working closely with them on Helix's next growth chapter" said Artur Gabor, Chief Executive Officer.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. Helix is listed on the TSX under the symbol "HBP".
For more information, please contact:
Helix BioPharma Corp.
9120 Leslie Street, Suite 205 Richmond Hill, Ontario,L4B 3J9 Tel: 905-841-2300 x 233
Frank Michalargias, Chief Financial Officer ir@helixbiopharma.com
Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the Company's activities relating to DOS47, and statements regarding expected improvements to the Company's independence, diversification and corporate governance and the Company's expectations regarding strengthening its future growth capabilities. Forward-looking statements can further be identified by the use of forward-looking terminology such as "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", or "should" occur or be achieved, or comparable terminology referring to future events or results.
Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward- looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release.
The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation; the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Company's annual management's discussion and analysis for the year ended July 31, 2021 under the heading "Risks and Uncertainties" and Helix's Annual Information Form, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed under the Company's profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.
SOURCE: Helix BioPharma Corp.
View source version on accesswire.com:
https://www.accesswire.com/697809/Helix-Biopharma-Corp-Announces-Appointment-of-Permanent-CEO-and-Independent-Board-Members
FAQ
Who has been appointed as the new CEO of Helix BioPharma Corp?
What new members were added to Helix BioPharma's Board of Directors?
What is the purpose of the new appointments at Helix BioPharma?
When were the new appointments announced for Helix BioPharma?
How might the leadership changes affect Helix BioPharma's growth?
